Exscientia Ltd is a biotechnology company that specializes in the application of artificial intelligence and machine learning to drug discovery and development. By leveraging advanced computational techniques, Exscientia aims to accelerate the identification and optimization of new therapeutic compounds, ultimately enhancing the efficiency and effectiveness of the drug development process. The company's innovative approach not only focuses on discovering novel drugs but also tailors them to the specific needs of patients, thereby aiming to improve treatment outcomes across various disease areas. Through collaborations with pharmaceutical companies and research institutions, Exscientia is at the forefront of transforming traditional drug development methodologies into a more data-driven and targeted approach.
Discover 2 compelling AI stocks NVIDIA (NASDAQ: NVDA) has invested in. Learn how the AI leader's vision can guide your portfolio in the tech revolution.
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion creating a vertically-integrated and technology-enabled drug discovery platform. Exscientia ADSs (Nasdaq: EXAI) ceased trading and will be delisted from Nasdaq.
Exscientia plc (Nasdaq: EXAI) today announced the advancement of two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving an aggregate of $15 million in milestone payments. Both lead compounds have met the product profile requirements, set by both Exscientia and Sanofi, to enable a transition to the lead optimisation phase within the collaboration. Both programmes have also shown a high level of differentiation in early profiling and have the potential to produce best-in-class assets.
Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36th EORTC-NCI-AACR (ENA) Symposium 2024 from October 23-25, in Barcelona, Spain.
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug Discovery Stocks Portfolio by 6.6% on the day.
Exscientia plc (Nasdaq: EXAI) today announced that David Hallett, interim Chief Executive Officer and Chief Scientific Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 7:00 a.m. EDT (12:00 p.m. BST).
Exscientia plc (Nasdaq: EXAI): Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2024, are summarised below.
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion by then.
PALM BEACH, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The technological shift driven by the rise of artificial intelligence (AI) is giving patients in the USA cautious optimism towards the potential of generative AI in healthcare. In order to safely bring AI into the healthcare space, state governments across the USA are working on how to regulate its implementation. The potential to enhance accuracy and speed in diagnostics, analyzing eye scans and predicting complications, and even designing new drugs, the potential for AI in healthcare is too big to ignore. Reaching the goal of safely bringing AI into the medical space still requires lots of research and development, with several tech innovators recently updating the market with their latest developments, including: Avant Technologies Inc. (OTCQB: AVAI), Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), Exscientia plc (NASDAQ: EXAI), Twist Bioscience Corporation (NASDAQ: TWST) and IQVIA Holdings Inc. (NYSE: IQV).
Exscientia merges with Recursion Pharmaceuticals in an all-stock deal. The new entity, named Recursion, will focus on industrializing drug discovery with advanced AI technologies, boasting $850 million in cash and expected synergies of $100 million annually.
To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under consideration.
Exscientia plc (Nasdaq: EXAI) today announced it has reached an agreement to acquire GT Apeiron’s share of its oral CDK7 inhibitor programme, gaining full control of GTAEXS617 (‘617) and all related intellectual property.
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average, in June and are now UP 13.8%, on average, YTD.
Exscientia plc (Nasdaq: EXAI) today announced it will be expanding its work with Amazon Web Services (AWS) to use the cloud provider’s artificial intelligence (AI) and machine learning (ML) services to power its platform for end-to-end drug discovery and automation.
